Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (171-180 of 312) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate CancerEric J Small, Raymond S Lance, Thomas A Gardner, et al.
Future Oncology (London, England)|January 26, 2022
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study designNeeraj Agarwal, Arun Azad, Neal D Shore, et al.
Future Oncology (London, England)|August 11, 2022
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Neal D Shore, et al.
JAMA Oncology|March 7, 2024
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate CancerDaniel E Spratt, Daniel J George, Neal D Shore, et al.
BJU International|July 31, 2025
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamideNicole Handa, Neal D Shore, Matthew R Cooperberg, et al.
The Journal of Urology|September 26, 2015
Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate CancerNeal D Shore, Naveen Kella, Brian Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsEmmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, et al.
Clinical Genitourinary Cancer|July 31, 2025
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II StudyNeal D Shore, K Kent Chevli, Daniel Saltzstein, et al.
The Journal of Urology|May 13, 2026
Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multi-Center Validation StudyDuncan H Whitney, Matthew Clay, Joel Wipperfurth, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancerUlka N Vaishampayan, Marianne Keessen, Robert Dreicer, et al.
Pageof 32

Showing results (171-180 of 312) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate CancerEric J Small, Raymond S Lance, Thomas A Gardner, et al.
Future Oncology (London, England)|January 26, 2022
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study designNeeraj Agarwal, Arun Azad, Neal D Shore, et al.
Future Oncology (London, England)|August 11, 2022
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancerNeeraj Agarwal, Arun Azad, Neal D Shore, et al.
JAMA Oncology|March 7, 2024
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate CancerDaniel E Spratt, Daniel J George, Neal D Shore, et al.
BJU International|July 31, 2025
Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamideNicole Handa, Neal D Shore, Matthew R Cooperberg, et al.
The Journal of Urology|September 26, 2015
Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate CancerNeal D Shore, Naveen Kella, Brian Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE TrialsEmmanuel S Antonarakis, Sumit K Subudhi, Christopher M Pieczonka, et al.
Clinical Genitourinary Cancer|July 31, 2025
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II StudyNeal D Shore, K Kent Chevli, Daniel Saltzstein, et al.
The Journal of Urology|May 13, 2026
Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multi-Center Validation StudyDuncan H Whitney, Matthew Clay, Joel Wipperfurth, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancerUlka N Vaishampayan, Marianne Keessen, Robert Dreicer, et al.
Pageof 32